Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Metro-PD1: a Phase I/II Trial Evaluating Anti-PD1 (Nivolumab) in Combination With Metronomic Chemotherapy in Children and Teenagers With Refractory / Relapsing Solid Tumors

NCT03585465 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.

NCT NCT03585465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03585465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Metro-PD1: a Phase I/II Trial Evaluating Anti-PD1 (Nivolumab) in Combination With Metronomic Chemotherapy in Children and Teenagers With Refractory / Relapsing Solid Tumors
Lead sponsor
Centre Oscar Lambret
Phase
Phase 1/2
Overall status
Terminated
Start date
March 26, 2019
Completion date
December 27, 2025
Enrollment
63 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

childhood solid tumor